Could Vtv Therapeutics Inc – Class A (NASDAQ:VTVT) Skyrocket? The Stock Had Too Little Sellers

June 14, 2018 - By Kristen Paramore

The stock of Vtv Therapeutics Inc – Class A (NASDAQ:VTVT) registered a decrease of 11.58% in short interest. VTVT’s total short interest was 1.44 million shares in June as published by FINRA. Its down 11.58% from 1.63 million shares, reported previously. With 6.28 million shares average volume, it will take short sellers 0 days to cover their VTVT’s short positions. The short interest to Vtv Therapeutics Inc – Class A’s float is 21.17%.

The stock increased 1.21% or $0.02 during the last trading session, reaching $1.67. About 182,917 shares traded. vTv Therapeutics Inc. (NASDAQ:VTVT) has declined 66.46% since June 14, 2017 and is downtrending. It has underperformed by 79.03% the S&P500.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company has market cap of $55.77 million. The company??s drug candidate for the treatment of Alzheimer??s disease comprise azeliragon , an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. It currently has negative earnings. The Company’s type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials.

More notable recent vTv Therapeutics Inc. (NASDAQ:VTVT) news were published by: Streetinsider.com which released: “Pre-Open Movers 05/31: (MDGL) (VTVT) (GM) Higher; (CLSD) (CRSP) (DLTR) Lower (more…)” on May 31, 2018, also 247Wallst.com with their article: “How Newsoara Bio Is Saving vTv Therapeutics” published on May 31, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: vTv Swoons On Failed Alzheimer’s Trial, Regenxbio Gets FDA Fast Track For RGX-111” on June 13, 2018. More interesting news about vTv Therapeutics Inc. (NASDAQ:VTVT) were released by: Seekingalpha.com and their article: “Vtv Therapeutics’ azeliragon flunks late-stage Alzheimer’s study; shares halted” published on June 12, 2018 as well as Nasdaq.com‘s news article titled: “Research Report Identifies Avangrid, Entercom Communications, Kennedy-Wilson, Emerson Electric, Amgen, and vTv …” with publication date: June 12, 2018.

vTv Therapeutics Inc. (NASDAQ:VTVT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: